A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease ; volume:16 ; number:1 ; day:16 ; month:6 ; year:2016 ; pages:1-13 ; date:12.2016
BMC neurology ; 16, Heft 1 (16.6.2016), 1-13, 12.2016
- Creator
-
McGhee, David J. M.
- Contributor
-
Ritchie, Craig W.
Zajicek, John P.
Counsell, Carl E.
SpringerLink (Online service)
- DOI
-
10.1186/s12883-016-0606-3
- URN
-
urn:nbn:de:1111-2016061722677
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- McGhee, David J. M.
- Ritchie, Craig W.
- Zajicek, John P.
- Counsell, Carl E.
- SpringerLink (Online service)
Other Objects (12)
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease